Concepedia

Aishwarya Krishnan

AK

Statistics

Publications

7

Citations

272

H-Index

7

Active since

2019

Affiliations

Memorial Sloan Kettering Cancer Center(Current)

University of Pennsylvania

Icahn School of Medicine at Mount Sinai

Mayo Clinic in Arizona

Aishwarya Krishnan is an author at Memorial Sloan Kettering Cancer Center specializing in jak2 mutations, life sciences, and myeloproliferative neoplasms.

ORCID

Publications per year

2019–2024

7

Publications

7

PRMT5 Inhibition Modulates E2F1 Methylation and Gene-Regulatory Networks Leading to Therapeutic Efficacy in JAK2V617F-Mutant MPN

Friederike Pastore, Neha Bhagwat, Alessandro Pastore et al. · Cancer Discovery · 2020 · 81 citations · Full text

, , +17

Phase 2 study of ruxolitinib and decitabine in patients with myeloproliferative neoplasm in accelerated and blast phase

John Mascarenhas, Raajit K. Rampal, Heidi Kosiorek et al. · Blood Advances · 2020 · 72 citations · Full text

, , +10

CXCL8/CXCR2 signaling mediates bone marrow fibrosis and represents a therapeutic target in myelofibrosis

Andrew Dunbar, Dongjoo Kim, Min Lü et al. · Blood · 2023 · 37 citations · Full text

, , +12

BMP2/SMAD pathway activation in JAK2/p53-mutant megakaryocyte/erythroid progenitors promotes leukemic transformation

Bing Li, Wenbin An, Hua Wang et al. · Blood · 2022 · 35 citations · Full text

, , +15

Therapeutic Efficacy of Combined JAK1/2, Pan-PIM, and CDK4/6 Inhibition in Myeloproliferative Neoplasms

Raajit K. Rampal, Maria Pinzon-Ortiz, Amritha Varshini Hanasoge Somasundara et al. · Clinical Cancer Research · 2021 · 22 citations · Full text

, , +17

1–5 of 7